{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:55:17Z","timestamp":1792760117660,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.intimp.2024.113736","type":"journal-article","created":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T05:25:52Z","timestamp":1733808352000},"page":"113736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Bevacizumab increases cisplatin efficacy by inhibiting epithelial\u2013mesenchymal transition via ALDH1 in cervical carcinoma"],"prefix":"10.1016","volume":"145","author":[{"given":"Na","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7081-1726","authenticated-orcid":false,"given":"Yuhua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2024.113736_b0005","doi-asserted-by":"crossref","unstructured":"Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, 71(3), 209\u2013249. 10.3322\/caac.21660.","DOI":"10.3322\/caac.21660"},{"key":"10.1016\/j.intimp.2024.113736_b0010","doi-asserted-by":"crossref","unstructured":"S, D., A, B., T, M., G, R., Ag, M., Ur, W., \u2026 C, G. P. D. (2023). Molecular mechanisms augmenting resistance to current therapies in clinics among cervical cancer patients. Medical oncology (Northwood, London, England), 40(5). 10.1007\/s12032-023-01997-9.","DOI":"10.1007\/s12032-023-01997-9"},{"key":"10.1016\/j.intimp.2024.113736_b0015","article-title":"Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.113736_b0020","doi-asserted-by":"crossref","unstructured":"R, B., T, D., L, K., S, K., R, S., M, G., \u2026 A, D. (2022). Cellular landscaping of cisplatin resistance in cervical cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 153. 10.1016\/j.biopha.2022.113345.","DOI":"10.1016\/j.biopha.2022.113345"},{"key":"10.1016\/j.intimp.2024.113736_b0025","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6550388","article-title":"TAB2 Promotes the Stemness and Biological Functions of Cervical Squamous Cell Carcinoma Cells","volume":"2021","author":"Zhou","year":"2021","journal-title":"Stem Cells Int."},{"issue":"1","key":"10.1016\/j.intimp.2024.113736_b0030","first-page":"7","article-title":"Cervical cancer stem cell-associated genes: Prognostic implications in cervical cancer","volume":"18","author":"Organista-Nava","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.intimp.2024.113736_b0035","doi-asserted-by":"crossref","unstructured":"N, C., H, K., J, K., J, L., Yh, P., Hn, S., & T, K. (2020). BRM270 targets cancer stem cells and augments chemo-sensitivity in cancer. Oncology letters, 20(4). 10.3892\/ol.2020.11964.","DOI":"10.3892\/ol.2020.11964"},{"key":"10.1016\/j.intimp.2024.113736_b0040","doi-asserted-by":"crossref","unstructured":"B, D., Sr, D., H, P., S, S., S, B., S, P., \u2026 Cn, K. (2023). Quinacrine inhibits HIF-1\u03b1\/VEGF-A mediated angiogenesis by disrupting the interaction between cMET and ABCG2 in patient-derived breast cancer stem cells. Phytomedicine\u00a0: international journal of phytotherapy and phytopharmacology, 117. 10.1016\/j.phymed.2023.154914.","DOI":"10.1016\/j.phymed.2023.154914"},{"key":"10.1016\/j.intimp.2024.113736_b0045","doi-asserted-by":"crossref","unstructured":"Y, C., S, L., Y, H., W, W., K, W., S, F., \u2026 X, Y. (2023). Glioma-derived small extracellular vesicles induce pericyte-phenotype transition of glioma stem cells under hypoxic conditions. Cellular signaling, 109. 10.1016\/j.cellsig.2023.110754.","DOI":"10.1016\/j.cellsig.2023.110754"},{"issue":"11","key":"10.1016\/j.intimp.2024.113736_b0050","doi-asserted-by":"crossref","first-page":"9606","DOI":"10.3390\/ijms24119606","article-title":"E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of VEGFR2-Mediated Signaling Pathways","volume":"24","author":"Huang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2024.113736_b0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/cpr.12216","article-title":"Cervical cancer stem cells","volume":"48","author":"Yao","year":"2015","journal-title":"Cell Prolif."},{"issue":"9","key":"10.1016\/j.intimp.2024.113736_b0060","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1158\/1078-0432.CCR-21-1299","article-title":"DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer","volume":"28","author":"Kurani","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.intimp.2024.113736_b0065","doi-asserted-by":"crossref","first-page":"11018","DOI":"10.18632\/oncotarget.6920","article-title":"Aldehyde dehydrogenase 1A1 in stem cells and cancer","volume":"7","author":"Tomita","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.intimp.2024.113736_b0070","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/jop.12734","article-title":"CD44 and ALDH1 immunoexpression as prognostic indicators of invasion and metastasis in oral squamous cell carcinoma","volume":"47","author":"Ortiz","year":"2018","journal-title":"Journal of Oral Pathology & Medicine: Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology"},{"issue":"1","key":"10.1016\/j.intimp.2024.113736_b0075","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41388-020-01518-2","article-title":"Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma","volume":"40","author":"Nimmakayala","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2024.113736_b0080","doi-asserted-by":"crossref","unstructured":"D, F., C, P., C, L., Y, Z., M, L., B, L., \u2026 Z, T. (2009). Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncology reports, 22(5). 10.3892\/or_00000545.","DOI":"10.3892\/or_00000545"},{"issue":"2","key":"10.1016\/j.intimp.2024.113736_b0085","first-page":"e1144","article-title":"Potential role of cancer stem cells as biomarkers and therapeutic targets in cervical cancer. Cancer Reports (Hoboken","volume":"2","author":"Sudhalkar","year":"2019","journal-title":"N.J.)"},{"key":"10.1016\/j.intimp.2024.113736_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2024.113736_b0095","doi-asserted-by":"crossref","unstructured":"Garcia-Mayea, Y., Mir, C., Masson, F., Paciucci, R., & LLeonart, M. E. (2020). Insights into new mechanisms and models of cancer stem cell multidrug resistance. Seminars in Cancer Biology, 60, 166\u2013180. 10.1016\/j.semcancer.2019.07.022.","DOI":"10.1016\/j.semcancer.2019.07.022"},{"issue":"2","key":"10.1016\/j.intimp.2024.113736_b0100","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","article-title":"Tumor metastasis: molecular insights and evolving paradigms","volume":"147","author":"Valastyan","year":"2011","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.intimp.2024.113736_b0105","article-title":"Microtubules Inhibit E-Cadherin Adhesive Activity by Maintaining Phosphorylated p120-Catenin in a Colon Carcinoma Cell Model","volume":"11","author":"Sl","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2024.113736_b0110","doi-asserted-by":"crossref","unstructured":"L, S., & Wi, W. (2009). Structure and biochemistry of cadherins and catenins. Cold Spring Harbor perspectives in biology, 1(3). 10.1101\/cshperspect.a003053.","DOI":"10.1101\/cshperspect.a003053"},{"issue":"2","key":"10.1016\/j.intimp.2024.113736_b0115","doi-asserted-by":"crossref","first-page":"237","DOI":"10.4103\/ijpm.ijpm_530_21","article-title":"Relationship of E-cadherin, Beta-catenin, N-cadherin, ZEB1 and \u03b1SMA as Epithelial Mesenchymal Transition markers with prognostic factors in early and advanced stage laryngeal squamous cell carcinomas","volume":"66","author":"Kucuk","year":"2023","journal-title":"Indian J. Pathol. Microbiol."},{"issue":"8","key":"10.1016\/j.intimp.2024.113736_b0120","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1111\/jcmm.14398","article-title":"COPB2 is upregulated in breast cancer and plays a vital role in the metastasis via N-cadherin and Vimentin","volume":"23","author":"Bhandari","year":"2019","journal-title":"J. Cell Mol. Med."},{"issue":"4","key":"10.1016\/j.intimp.2024.113736_b0125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1242\/dev.111.4.983","article-title":"The snail gene required for mesoderm formation in Drosophila is expressed dynamically in derivatives of all three germ layers","volume":"111","author":"Alberga","year":"1991","journal-title":"Development"},{"key":"10.1016\/j.intimp.2024.113736_b0130","doi-asserted-by":"crossref","unstructured":"Sj, S.-G., M, M., & Sk, A. (2016). Regulation of epithelial\u2013mesenchymal transition through epigenetic and posttranslational modifications. Molecular cancer, 15. 10.1186\/s12943-016-0502-x.","DOI":"10.1186\/s12943-016-0502-x"},{"key":"10.1016\/j.intimp.2024.113736_b0135","doi-asserted-by":"crossref","unstructured":"J, G., Hi, H., Ab, S., D, M., Rl, C., R, D., & Ol, C. (2020). Bevacizumab (Avastin\u00ae) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer treatment reviews, 86. 10.1016\/j.ctrv.2020.102017.","DOI":"10.1016\/j.ctrv.2020.102017"},{"issue":"5","key":"10.1016\/j.intimp.2024.113736_b0140","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/jcm8050612","article-title":"Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer","volume":"8","author":"Sabatier","year":"2019","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.113736_b0145","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/cam4.3767","article-title":"CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma","volume":"10","author":"Nishikawa","year":"2021","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.113736_b0150","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/tpj.2011.61","article-title":"Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy","volume":"13","author":"Pohl","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.intimp.2024.113736_b0155","doi-asserted-by":"crossref","unstructured":"Arai, H., Millstein, J., Loupakis, F., Stintzing, S., Wang, J., Battaglin, F., \u2026 Lenz, H.-J. (2021). Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. European Journal of Cancer (Oxford, England: 1990), 150, 133\u2013142. 10.1016\/j.ejca.2021.03.048.","DOI":"10.1016\/j.ejca.2021.03.048"},{"issue":"2","key":"10.1016\/j.intimp.2024.113736_b0160","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ijrobp.2010.09.043","article-title":"Prognostic cell biological markers in cervical cancer patients primarily treated with (chemo)radiation: a systematic review","volume":"79","author":"Noordhuis","year":"2011","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"9","key":"10.1016\/j.intimp.2024.113736_b0165","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.3390\/cells10092371","article-title":"HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells","volume":"10","author":"Lee","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.intimp.2024.113736_b0170","doi-asserted-by":"crossref","unstructured":"S, A.-T., Md, R., & Rj, L. (1999). Notch signaling: cell fate control and signal integration in development. Science (New York, N.Y.), 284(5415). 10.1126\/science.284.5415.770.","DOI":"10.1126\/science.284.5415.770"},{"issue":"10","key":"10.1016\/j.intimp.2024.113736_b0175","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1084\/jem.20111855","article-title":"Oncogenic and tumor suppressor functions of Notch in cancer: it\u2019s NOTCH what you think","volume":"208","author":"Lobry","year":"2011","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.intimp.2024.113736_b0180","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.intimp.2024.113736_b0185","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-22-0243","article-title":"Targeting the DLL\/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development","volume":"22","author":"You","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2024.113736_b0190","doi-asserted-by":"crossref","unstructured":"N, E., M, A., Ss, F., Pg, K., V, S.-M., S, A., \u2026 Ar, A. (2023). Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance. Critical reviews in oncology\/hematology, 182. 10.1016\/j.critrevonc.2023.103920.","DOI":"10.1016\/j.critrevonc.2023.103920"},{"key":"10.1016\/j.intimp.2024.113736_b0195","doi-asserted-by":"crossref","unstructured":"V, S., & I, L. (2022). Understanding pancreatic cancer stem cells and their role in carcinogenesis: a narrative review. Stem cell investigation, 9. 10.21037\/sci-2021-067.","DOI":"10.21037\/sci-2021-067"},{"key":"10.1016\/j.intimp.2024.113736_b0200","doi-asserted-by":"crossref","unstructured":"L, G., N, E., K, A., & W, A. (2020). Notch1 in Cancer Therapy: Possible Clinical Implications and Challenges. Molecular pharmacology, 98(5). 10.1124\/molpharm.120.000006.","DOI":"10.1124\/molpharm.120.000006"},{"issue":"1","key":"10.1016\/j.intimp.2024.113736_b0205","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-017-0507-3","article-title":"Notch signaling plays a crucial role in cancer stem-like cells maintaining stemness and mediating chemotaxis in renal cell carcinoma","volume":"36","author":"Xiao","year":"2017","journal-title":"Journal of Experimental & Clinical Cancer Research: CR"},{"key":"10.1016\/j.intimp.2024.113736_b0210","doi-asserted-by":"crossref","unstructured":"T, S., D, Z., Z, W., B, Z., Y, L., X, S., \u2026 J, S. (2021). Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial\u2013mesenchymal transition process. Environmental toxicology, 36(9). 10.1002\/tox.23296.","DOI":"10.1002\/tox.23296"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924022586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924022586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T19:41:37Z","timestamp":1734637297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924022586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"alternative-id":["S1567576924022586"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113736","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bevacizumab increases cisplatin efficacy by inhibiting epithelial\u2013mesenchymal transition via ALDH1 in cervical carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.113736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113736"}}